PDS Biotech to Announce Second Quarter Financial Results on August 13, 2024
PRINCETON, N.J., Aug. 07, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage...
Day: August 7, 2024
Accolade To Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase
SEATTLE, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the...
PROPHASE LABS INC. TO PRESENT SECOND QUARTER 2024 FINANCIAL RESULTS ON AUGUST 14
GARDEN CITY, NY, Aug. 07, 2024 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), announced today that they will be...
CarnoSyn® Brands Unveils TriBsyn™ – “The World’s First Paresthesia-Free Beta-Alanine Powder”
CARLSBAD, Calif., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Exclusively from Natural Alternatives International, Inc. (NAI), CarnoSyn® Brands portfolio of patented...
Immutep to Participate in Upcoming Investor Conferences
SYDNEY, AUSTRALIA, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology...
NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
-- Reported positive topline data from pivotal Phase 3 BROOKLYN trial evaluating obicetrapib in patients with HeFH; achieved primary endpoint...
Tr1X Announces FDA Clearance of IND Application for TRX103, an Allogeneic Engineered Tr1 Treg Cell Therapy for Treatment-Refractory Crohn’s Disease
Tr1X Plans to Initiate a Phase 1/2a study and Dose the First Patient by the End of 2024SAN DIEGO, Aug....
Optimi Health Announces Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - August 7, 2024) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or...
Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024
STONY BROOK, NY / ACCESSWIRE / August 7, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"),...
Modular Medical Initiates Transfer of Manufacturing Operations to Phillips Medisize
SAN DIEGO, CA / ACCESSWIRE / August 7, 2024 / Modular Medical, Inc. (the "Company" or "Modular Medical") (NASDAQ:MODD), an...
Evotec SE Reports First Half-year 2024 Results on 14 August 2024
HAMBURG, GERMANY / ACCESSWIRE / August 7, 2024 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will...
LPW Training Services Named 2024 Best Company for Women to Work
Women's Choice Award® Names LPW Training Services a 2024 Best Companies to Work for WomenSOMERVILLE, NJ / ACCESSWIRE / August...
Opkit Rolls Out Back-of-Office Generative AI Call Center for Medical Practices With a Human-in-the-Loop Model
Comprehensive Solution Performs Calls Faster, More Accurately, and Less Expensively than Offshore BPOs and Regular Staff NEW YORK, NY /...
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11
MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 Initiated Phase 3...
Ultimovacs Announces Notice of Resignation from Deputy Board Member
Oslo, August 7, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI) today announced that it has received notice from deputy board member...
ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation
Data demonstrate that extracellular ASC specks, independent of IL-1β, govern the pathogenesis and extent of amyloid A (AA) amyloidosis, which...
Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development...
Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance
CAPLYTA Q2 2024 net product sales were $161.3 million, compared to $110.1 million for the same period in 2023, representing a...
Quotient Therapeutics Appoints Peter Campbell, Ph.D. as Chief Scientific Officer
Company’s academic co-founder from the Wellcome Sanger Institute will lead Quotient’s Somatic Genomics researchCAMBRIDGE, Mass., Aug. 07, 2024 (GLOBE NEWSWIRE)...
Ocular Therapeutix™ Reports Second Quarter 2024 Results
SOL-R AXPAXLI™ Repeat Dosing Study in Wet AMD Acceptable to FDA as Registrational Trial Enrollment in SOL-1 Continues to Accelerate...